Clairvoyant Networks, Inc., creators of Theora Care, has joined the 2026 Inc. 5000 list at No. 2976. This ranking recognizes the company’s swift growth in the healthcare and data analytics sectors, placing it among the most dynamic private businesses in the country.

Paramedics in The Villages are now using handheld ultrasound devices to deliver rapid diagnostics straight from the field. This high-tech approach underscores a broader shift toward advanced emergency care and community health innovation.

This article explores findings from the Philips Future Health Index 2026, which highlight AI’s rising influence on the medical field. According to the report, artificial intelligence is already saving clinicians time and delivering visible, measurable benefits in healthcare.

A newly launched AI prescribing assistant from MEDvidi seeks to address the growing mental health access crisis in the United States. By focusing on prescription renewal and patient capacity, this innovation aims to enhance the delivery of crucial mental health services nationwide.

At its 28th annual Cheers Awards, the Institute for Safe Medication Practices spotlighted leaders who have advanced medication safety nationwide. By harnessing innovative technology and best practices, these champions demonstrate an unwavering commitment to reducing healthcare risks and enhancing patient well-being.

CentralReach has appointed Peter Boumenot as its new Chief Product Officer, adding his two decades of healthcare tech experience to the leadership team. This move highlights the company’s commitment to innovating its software platform for autism and IDD care providers.

The global healthcare claims management market is projected to escalate from USD 50.32 billion in 2025 to USD 334.6 billion by 2034. Accelerating adoption of digital tools and heightened focus on efficiency are fueling this remarkable uptick, with experts citing a 23.43% annual growth rate.

Maple Capital Management Inc. has reduced its stake in Medtronic PLC by 5.2% during the first quarter, selling 165 shares in the process. The move leaves the institutional investor with 3,015 shares of the medical device giant, now valued at approximately $271,000.

Panagora Asset Management Inc. recently revealed a sharp reduction in its Omnicell stake. According to an SEC filing, the asset manager cut its shares by 70.3%, selling over 114,000 shares during the first quarter.